Fontan Procedure in India and UAE | Complete Patient Guide

• ELIGIBLE PATIENTS:

• Children aged 18 months to 4 years who have previously undergone a successful bidirectional Glenn (Stage II) procedure and demonstrate favorable hemodynamics

• Patients with functional single-ventricle anatomy including hypoplastic left heart syndrome (HLHS), tricuspid atresia, double-inlet left ventricle (DILV), pulmonary atresia with intact ventricular septum (PA-IVS), and heterotaxy syndrome

• Patients with pulmonary vascular resistance (PVR) less than 2–3 Wood units (indexed)

• Mean pulmonary artery pressure (mPAP) less than 15 mmHg on pre-operative cardiac catheterization

• Preserved single-ventricle systolic function (ejection fraction or fractional area of change within acceptable limits on echocardiography)

• Absence of significant atrioventricular valve regurgitation (mild or less on echocardiography is preferred)

• Adequate pulmonary artery size and architecture (McGoon ratio or Nakata index within acceptable range on CT angiography)

• REQUIRED PRE-OPERATIVE DIAGNOSTICS:

• Cardiac catheterization with hemodynamic assessment (pulmonary vascular resistance, pulmonary artery pressure, ventricular end-diastolic pressure, Qp:Qs ratio)

• Transthoracic echocardiography (TTE) and/or transesophageal echocardiography (TEE): ventricular function, AV valve competence, anatomy

• Cardiac MRI (CMR): precise volumetric assessment of ventricular volumes, ejection fraction, and pulmonary artery morphology

• CT pulmonary angiography (CTPA): pulmonary artery anatomy and branch caliber

• Comprehensive metabolic panel, complete blood count, coagulation studies (PT/INR, aPTT)

• Liver function tests and hepatic ultrasound (especially if prior Fontan or prolonged passive venous congestion)

• Brain natriuretic peptide (BNP) or NT-proBNP for ventricular stress assessment

• Formal developmental/neurodevelopmental evaluation

• CONTRAINDICATIONS (ABSOLUTE):

• Pulmonary vascular resistance ≥ 4 Wood units (indexed) — prohibitively high risk of Fontan failure

• Mean pulmonary artery pressure > 18–20 mmHg

• Severe ventricular systolic dysfunction

• Severe or unrepaired atrioventricular valve regurgitation

• Significantly hypoplastic, distorted, or stenotic pulmonary arteries not amenable to surgical reconstruction

• Uncontrolled systemic infection or sepsis

• RELATIVE CONTRAINDICATIONS:

• Moderate ventricular dysfunction (requires individualized risk-benefit analysis)

• Moderate AV valve regurgitation (may require concurrent valve repair)

• Heterotaxy with complex pulmonary venous anomalies

• Prior failed Stage II palliation with residual anatomic distortion

SURGICAL TECHNIQUE OPTIONS FOR FONTAN COMPLETION:

1. EXTRACARDIAC CONDUIT (ECC) FONTAN — CURRENT GOLD STANDARD: The extracardiac conduit technique involves anastomosing a ringed Gore-Tex (polytetrafluoroethylene / ePTFE) tube graft (typically 18–22 mm in diameter, selected based on patient weight and body surface area) between the divided infradiaphragmatic inferior vena cava and the undersurface of the pulmonary artery confluence. The conduit lies entirely outside the heart muscle, eliminating suture lines within the atrium. Key advantages include the ability to perform the procedure without (or with minimal) cardiopulmonary bypass using the 'off-pump' or 'beating heart' technique in selected cases, reduced incidence of sinus node dysfunction and atrial arrhythmias compared to intra-atrial techniques, and preservation of atrial geometry. A small fenestration (3–4 mm) may be created between the conduit and the atrium to serve as a 'pop-off valve,' reducing early post-operative Fontan pressure and improving cardiac output at the cost of mild residual cyanosis.

2. LATERAL TUNNEL (LT) FONTAN — ESTABLISHED ALTERNATIVE: The lateral tunnel technique uses a combination of pericardial patch and the posterior wall of the right atrium to construct an intra-atrial baffle that channels IVC flow to the pulmonary arteries. This technique requires cardioplegic arrest and cardiopulmonary bypass. It offers excellent long-term hemodynamics and may be preferred in patients with specific anatomical considerations. Fenestration can similarly be incorporated. Long-term data show comparable survival to ECC, but a slightly higher rate of late atrial arrhythmias due to the extensive intra-atrial suture lines.

3. FENESTRATED FONTAN: In higher-risk patients (borderline hemodynamics, elevated PVR, depressed ventricular function), a deliberate 4mm fenestration is created between the Fontan circuit and the atrium. This decompresses the venous circuit, maintains cardiac output during the early post-operative period, and reduces pleural effusions. The fenestration can be subsequently closed percutaneously (transcatheter device closure) in the cardiac catheterization laboratory once the patient has adapted to the Fontan physiology — typically 6–12 months post-surgery.

4. OFF-PUMP / BEATING-HEART EXTRACARDIAC FONTAN: A significant technical advance at high-volume centers, the off-pump ECC Fontan avoids the systemic inflammatory response, hemodilution, and myocardial ischemia associated with cardiopulmonary bypass. By using temporary IVC snaring and constructing the conduit on a beating heart with maintained systemic perfusion, outcomes data show reduced ICU stay, lower transfusion requirements, and faster recovery. This is not universally applicable and requires meticulous anatomical suitability.

5. CARDIAC CATHETERIZATION & INTERVENTIONAL ADJUNCTS: Hybrid approaches include pre-Fontan interventional catheterization to dilate or stent stenotic pulmonary artery branches, coil or device embolization of significant aortopulmonary collaterals (APCs) that would otherwise steal flow and increase ventricular volume load, and post-Fontan transcatheter fenestration closure. 3D echocardiography and intraoperative TEE are employed for real-time surgical guidance.

6. VENTRICULAR ASSIST DEVICES (VAD) & TRANSPLANTATION (SALVAGE): For patients with failing Fontan circulation — characterized by progressive ventricular dysfunction, protein-losing enteropathy refractory to medical management, or plastic bronchitis — ventricular assist device implantation (Berlin Heart EXCOR paracorporeal VAD in smaller children; HeartMate or HVAD in adolescents) as a bridge to cardiac transplantation represents the definitive salvage strategy. Specialized centers in India and the UAE with pediatric VAD programs offer this pathway.

STEP 1 — INITIAL CONSULTATION & REMOTE CASE REVIEW (WEEKS 1–2 BEFORE TRAVEL): Families submit complete medical records including operative reports from prior Stage I and Stage II surgeries, echocardiography reports, cardiac catheterization hemodynamic data, and recent labs to GAF Healthcare's medical coordination team. A senior pediatric cardiac surgeon reviews the file and provides a written surgical opinion, preliminary cost estimate, and recommended pre-travel investigations within 48–72 hours.

STEP 2 — PRE-OPERATIVE EVALUATION ON ARRIVAL (DAYS 1–3): Upon arrival, the patient is admitted to the pediatric cardiology department for 2–3 days of comprehensive pre-operative workup. This includes repeat echocardiography, repeat cardiac catheterization if hemodynamic data is >6 months old or if clinical status has changed, cardiac MRI, CT pulmonary angiography, complete laboratory studies, anesthesiology assessment, and family counseling sessions with the surgical team, cardiologist, and cardiac ICU nursing staff. Interventional catheterization for APC coiling may be performed during this phase if indicated.

STEP 3 — SURGERY DAY: The Fontan procedure is performed under general endotracheal anesthesia with continuous intraoperative transesophageal echocardiography (TEE) guidance. Cardiopulmonary bypass (CPB) is established (for lateral tunnel) or the procedure is performed off-pump (for extracardiac conduit in selected cases). Surgical duration is typically 3–5 hours. Vasopressin, milrinone, and phenoxybenzamine are commonly used in the intraoperative and early post-operative period to optimize pulmonary vasodilation and systemic vascular resistance.

STEP 4 — PEDIATRIC CARDIAC ICU (DAYS 1–7 POST-SURGERY): Patients are managed in the PCICU with ventilatory support initially, transitioning to extubation typically within 24–48 hours in uncomplicated cases. Key management priorities include: maintaining Fontan pressure 10–14 mmHg, optimizing preload, managing pleural effusions (chest drains are standard), initiating anticoagulation (unfractionated heparin transitioning to warfarin or aspirin per institutional protocol), and titrating pulmonary vasodilators (inhaled nitric oxide in early post-op period, transitioning to oral sildenafil). Nutritional support is initiated early.

STEP 5 — STEP-DOWN WARD & REHABILITATION (DAYS 8–21): Chest drains are removed once drainage is minimal (typically days 4–7). The child begins progressive mobilization with physiotherapy, oral feeding is optimized, and anticoagulation is stabilized. Echocardiography is repeated to confirm Fontan circuit patency and ventricular function. Parents receive structured education on post-discharge care, anticoagulation monitoring, dietary modifications (low-fat diet to reduce chylothorax risk), and activity restrictions. Discharge from hospital occurs at approximately days 14–21.

STEP 6 — POST-DISCHARGE MONITORING PERIOD IN COUNTRY (WEEKS 3–10): Patients remain in the destination country in a serviced apartment or guest house arranged by GAF Healthcare. Outpatient follow-up appointments are scheduled at 1–2 week intervals with the pediatric cardiologist to monitor: INR/anticoagulation levels, pleural effusion recurrence, wound healing, oxygen saturation, weight gain, and nutritional status. Repeat echocardiography is performed at 4 weeks.

STEP 7 — FIT-TO-FLY CLEARANCE & DEPARTURE (WEEKS 6–10): Fit-to-fly assessment is conducted by the treating cardiologist and surgeon. Clearance criteria include: hemodynamically stable Fontan circulation, oxygen saturation ≥90% on room air, resolved or minimal pleural effusions, healed sternotomy wound, therapeutic and stable anticoagulation, and absence of infection. Short-haul flights (under 4 hours) may be approved as early as 6 weeks; long-haul international flights are typically approved at 8–10 weeks. A detailed discharge summary, anticoagulation passport, and emergency contact protocols are provided to the family.

STEP 8 — LONG-TERM SURVEILLANCE (LIFELONG): Fontan patients require lifelong cardiology follow-up. GAF Healthcare coordinates with the patient's home cardiologist and provides a structured surveillance recommendation letter covering annual echocardiography, liver function testing (for FALD surveillance), Holter monitoring (arrhythmia surveillance), exercise stress testing, and periodic cardiac MRI every 3–5 years.